Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 15 February 2026, providing investors with the latest insights into its performance and outlook.

Shree Ganesh Remedies Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a recent uptick in share price, the company’s valuation now stands out against both historical averages and peer benchmarks, raising questions about price attractiveness amid mixed financial performance and market returns.

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 04 February 2026, providing investors with the most up-to-date analysis.

Shree Ganesh Remedies Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a recent price surge of 6.79% to ₹455.00, the stock’s overall momentum and technical indicators present a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Remedies Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently navigating a challenging technical landscape. Despite a modest daily price gain, the stock’s broader momentum indicators reveal a shift towards bearishness, with key technical parameters signalling caution for investors.

Shree Ganesh Remedies Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest daily price gain, the stock remains under pressure over longer periods, with technical indicators suggesting a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Remedies Ltd touched a fresh 52-week low of Rs.381.1 today, marking a significant decline in its stock price amid persistent downward momentum. The pharmaceutical company’s shares opened sharply lower and underperformed the sector, reflecting ongoing pressures in its financial performance and market positioning.

Shree Ganesh Remedies Ltd has reported a marked deterioration in its financial performance for the quarter ended December 2025, with key metrics such as revenue, profitability, and returns on capital contracting sharply. This downturn contrasts with the company’s historically robust growth trajectory and comes amid broader sectoral headwinds in Pharmaceuticals & Biotechnology.

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Shree Ganesh Remedies Ltd., a pharmaceutical intermediates and fine chemicals manufacturer with a market capitalisation of ₹546.00 crores, reported net profit of ₹4.96 crores for Q2 FY26, marking a sequential improvement of 43.77% quarter-on-quarter but a concerning year-on-year decline of 22.62%. The Ankleshwar-based company's stock has been under severe pressure, trading at ₹424.00 and down 38.68% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers.

Shree Ganesh Remedies Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.415 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Shree Ganesh Remedies Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. Despite a strong long-term performance, recent weekly and monthly charts reveal deteriorating momentum, prompting a downgrade in its Mojo Grade from Strong Sell to Sell as of 5 January 2026.

Shree Ganesh Remedies Ltd has exhibited a subtle shift in price momentum, reflected in a transition from a bearish to a mildly bearish technical trend. Despite a 1.76% gain on 6 Jan 2026, the stock’s technical indicators present a complex picture, with some oscillators signalling mild bullishness while others remain bearish, underscoring a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 20 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Shree Ganesh Remedies touched a new 52-week low of Rs.418 today, marking a significant decline in its stock price amid broader market gains and sectoral outperformance. The pharmaceutical company’s shares have been trading below all key moving averages, reflecting persistent pressures over the past year.